

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:		
James	s A. HOXIE)
Original U.S. Patent No. 5,994,515 Original Issue Date: November 30, 1999 Original Filing Date: June 25, 1997) Group Art Unit: Unassigned)
Reissue Application No.: 10/829,475 Reissue Application Filed: April 22, 2004		•) Examiner: Unassigned)
For:	CELLULAR IMMUNODI	ES DIRECTED AGAINST CORECEPTORS FOR HUMAN EFICIENCY VIRUS AND OF USING THE SAME))))
MAII	nissioner for Pa L STOP: REIS ington, D.C. 2	SSUE	,
Sir:			
		REISSUE DECLARATION BY IN	VENTOR
1.	I hereby declare that:		
2.	My residence, post office address and citizenship are as stated below next to my name.		
3.	I believe that I am the original, first inventor of the subject matter which is described and claimed in United States Patent No. 5,994,515, issued on November 30, 1999, and for which a reissue patent is sought on the invention entitled: ANTIBODIES DIRECTED AGAINST CELLULAR CORECEPTORS FOR HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME the specification of which		
	[] [X]	is attached hereto. was filed on April 22, 2004 as Reissur 10/829,475 and was amended on April 20.	* *

Attorney Docket No.: 053893-5047-01 Reissue Application of U.S. Patent.: 5,994,515

Page 2

4. I have reviewed and understand the contents of the above identified specification, including the claims as amended with the Submission of Reissue Patent Application.

- 5. I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.
- 6. I verily believe the original patent to be wholly or partly inoperative or invalid by reason of (check all that apply)
 - [X] the patentee claiming more than the patentee had the right to claim in the patent.[] a defective specification or drawing.
- 7. At least one error upon which this reissue application is based is described as follows:

The reissue includes amendments to the patent claims taking into account the adverse decision in Patent Interference No. 105,059 and the designation therein of claims 6 and 9 as not corresponding to the lost count. More specifically, claim 1 has been limited to the subject matter of claim 6. Also, claims 5 and 6 have been canceled as redundant. While claims 2-4, 7 and 8 were designated as corresponding to the interference count, these dependent claims have been retained in view of the indicated amendment of claim 1 to delete the interfering subject matter.

- 8. All errors corrected in this reissue application arose without any deceptive intention on the part of the Applicant.
- 9. I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all correspondence to: Customer Number: 09629

10. I hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.

Attorney Docket No.: 053893-5047-01 Reissue Application of U.S. Patent.: 5,994,515

Page 3

First Inventor:

James A. Hoxie

Residence: Berwyn, PA Citizenship: United States

Post Office Address: 560 Winston Way, Berwyn, PA, United States

James A Dxie

Signed:



PATENT ATTORNEY DOCKET NO. 053893-5047-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
James A. HOXIE)
Original U.S. Patent No. 5,994,515) Group Art Unit: Unassigned
Original Issue Date: November 30, 1999)
Original Filing Date: June 25, 1997)
Reissue Application No.: 10/829,475) Examiner: Unassigned
Reissue Application Filed: April 22, 2004)
For: ANTIBODIES DIRECTED AGAINST)
CELLULAR CORECEPTORS FOR HUMAN)
IMMUNODEFICIENCY VIRUS AND)
METHODS OF USING THE SAME)

Commissioner for Patents **MAIL STOP: REISSUE** Washington, D.C. 20231

Sir:

CONSENT OF ASSIGNEE TO REISSUE APPLICATION

Trustees of the University of Pennsylvania states that it is the assignee of the entire right, title, and interest in the above-referenced letters patent by virtue of a chain of title from the inventors, of the above-referenced letters patent, to the current assignee as shown below:

1. From: <u>James A. Hoxie</u> To: <u>Trustees of the University of Pennsylvania</u>

The document was recorded in the United States Patent and Trademark Office at Reel 008859, Frame 0203 on December 18, 1997.

Attorney Docket No.: 053893-5047-01 Reissue Application of U.S. Patent.: 5,994,515

Page 2

The undersigned, authorized to act on behalf of the assignee in the above-referenced letters patent, hereby consents to the accompanying reissue application.

Respectfully submitted,

Trustees of the University of Rennsylvania

By:

Name:

TIMOTHY J. RAYNOR

Title:

DIRECTOR, INTELLECTUAL PROPERTY

CENTER FOR TECHNOLOGY TRANSFER

UNIVERSITY OF PENNSYLVANIA